Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients.
Björn StällbergChrister JansonKarin LisspersGunnar JohanssonFlorian S GutzwillerKaren MezziBine Kjoeller BjerregaardAnne Mette Tranberg KejsLeif JorgensenKjell LarssonPublished in: NPJ primary care respiratory medicine (2020)
This study reports the association of ICS use and the risk of type 2 diabetes mellitus (T2DM) in Swedish patients with COPD using data from real-world, primary care settings. A total of 7078 patients with COPD were included in this analysis and the 5-year cumulative incidence rate per 100,000 person years was 1506.9. The yearly incidence rate per 100,000 person years ranged from 850 to 1919. Use of ICS especially at a high dose in patients with COPD was related to an increased risk of T2DM.
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- primary care
- type diabetes
- high dose
- end stage renal disease
- risk factors
- cystic fibrosis
- glycemic control
- ejection fraction
- newly diagnosed
- chronic kidney disease
- low dose
- prognostic factors
- patient reported outcomes
- stem cell transplantation
- machine learning
- general practice